(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of 84.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.51%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Werewolf Therapeutics's revenue in 2024 is $9,283,000.On average, 3 Wall Street analysts forecast HOWL's revenue for 2024 to be $141,157,935, with the lowest HOWL revenue forecast at $82,597,058, and the highest HOWL revenue forecast at $257,842,667. On average, 1 Wall Street analysts forecast HOWL's revenue for 2025 to be $2,185,107,350, with the lowest HOWL revenue forecast at $2,185,107,350, and the highest HOWL revenue forecast at $2,185,107,350.
In 2026, HOWL is forecast to generate $2,185,107,350 in revenue, with the lowest revenue forecast at $2,185,107,350 and the highest revenue forecast at $2,185,107,350.